ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
July 02 2021 - 6:30AM
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a
biotechnology company focused on the discovery and development of
antibody therapeutics targeting toxic oligomers implicated in the
development of neurodegenerative diseases, today announced the
voting results of the Corporation's annual meeting of shareholders
held on June 30, 2021 in Vancouver, British Columbia, Canada (the
"Meeting").
ProMIS Neurosciences is pleased to announce that
all resolutions described in the Management Proxy Circular and
placed before the Meeting were overwhelmingly approved by the
shareholders. The total number of common shares represented by
shareholders present by proxy at the meeting was
104,999,925, representing 34.32%
of the Corporation's outstanding common shares.
"This year’s Annual Meeting marks the sixth
anniversary of ProMIS Neurosciences," stated Eugene Williams,
ProMIS Executive Chairman. "On behalf of the Board of Directors and
the ProMIS management team I would like to sincerely thank our
shareholders for their on-going support. We look forward to
continued progress applying our unique technology platform to the
development of disease-modifying antibody therapies, diagnostics
and potential vaccines for neurodegenerative diseases, including
Alzheimer’s, ALS and Parkinson’s disease."
In particular, the following are the voting
results for the 103,137,426 common shares that
were voted in person or by proxy at the Meeting.
1. The following directors were
elected, with each nominee receiving a minimum majority of 75% of
the votes cast:
DIRECTOR |
FOR |
WITHHELD |
Eugene Williams |
55,876,666 |
18,219,274 |
Neil Cashman, M.D. |
73,388,087 |
707,853 |
Richard J. Gregory, PH.D. |
67,464,866 |
6,631,074 |
Patrick D. Kirwin |
67,364,166 |
6,731,744 |
Neil K. Warma |
69,534,991 |
4,560,949 |
William Wyman |
56,967,143 |
17,128,797 |
2. PricewaterhouseCoopers LLP,
Chartered Professional Accountants, were appointed auditor of the
Company and the Board authorized to fix the auditor’s remuneration.
Shares voted in person and by proxies received represented
103,279,732 votes FOR and 1,720,193 votes WITHHELD.
3. The ordinary resolution to
authorize the Corporation to grant options pursuant to the
Corporation’s 20% rolling Stock Option Plan until June 30, 2024 was
passed by a majority vote of the disinterested shareholders of the
Corporation. Shares voted in person and by proxies received
represented 27,706,467 votes FOR and 17,043,875 votes AGAINST. The
above vote tally on this resolution is of votes of the
disinterested shareholders only because votes representing
29,345,598 Common Shares of Insiders were excluded from the vote
tally.
About ProMIS Neurosciences
Inc.
ProMIS Neurosciences, Inc. is a development
stage biotechnology company focused on discovering and developing
antibody therapeutics selectively targeting toxic oligomers
implicated in the development and progression of neurodegenerative
diseases, in particular Alzheimer’s disease (AD), amyotrophic
lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s
proprietary target discovery engine is based on the use of two
complementary techniques. The Company applies its thermodynamic,
computational discovery platform -ProMIS™ and Collective
Coordinates - to predict novel targets known as Disease Specific
Epitopes on the molecular surface of misfolded proteins. Using this
unique approach, the Company is developing novel antibody
therapeutics for AD, ALS and PD. ProMIS is headquartered in
Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS
is listed on the Toronto Stock Exchange under the symbol PMN, and
on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS
Neurosciences, please consult the Company’s website at:
www.promisneurosciences.com
Follow us on Twitter, Like us on LinkedIn
For Investor Relations please contact: Alpine Equity Advisors
Nicholas Rigopulos, President nick@alpineequityadv.com Tel. 617
901-0785
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
information release may contain certain forward-looking
information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by statements herein, and therefore these statements should
not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jul 2023 to Jul 2024